{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:37Z","timestamp":1793325757259,"version":"4.5.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium avium<\/jats:named-content>\n                    complex is now the leading mycobacterial cause of chronic pneumonia in the United States. Macrolides and ethambutol form the backbone of the regimen used in the treatment of pulmonary disease. However, therapy outcomes remain poor, with microbial cure rates of 4% in cavitary disease. The treatment dose of azithromycin has mostly been borrowed from that used to treat other bacterial pneumonias; there are no formal dose-response studies in pulmonary\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. avium<\/jats:named-content>\n                    disease and the optimal dose is unclear. We utilized population pharmacokinetics and pharmacokinetics\/pharmacodynamics-derived azithromycin exposures associated with optimal microbial kill or resistance suppression to perform 10,000 patient Monte Carlo simulations of dose effect studies for daily azithromycin doses of 0.5 to 10 g. The currently recommended dose of 500 mg per day achieved the target exposures in 0% of patients. Exposures associated with optimal kill and resistance suppression were achieved in 87 and 54% of patients, respectively, only by the very high dose of 8 g per day. The azithromycin susceptibility breakpoint above which patients failed therapy on the very high doses of 8 g per day was an MIC of 16 mg\/liter, suggesting a critical concentration of 32 mg\/liter, which is 8-fold lower than the currently used susceptibility breakpoint of 256 mg\/liter. If the standard dose of 500 mg a day were used, then the critical concentration would fall to 2 mg\/liter, 128-fold lower than 256 mg\/liter. The misclassification of resistant isolates as susceptible could explain the high failure rates of current doses.\n                  <\/jats:p>","DOI":"10.1128\/aac.02854-15","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T22:49:13Z","timestamp":1453762153000},"page":"2157-2163","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease"],"prefix":"10.1128","volume":"60","author":[{"given":"Devyani","family":"Deshpande","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA"},{"name":"Department of Medicine, University of Cape Town, Observatory, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_2_3_2","first-page":"229","article-title":"Trends in tuberculosis\u2013United States, 2013","volume":"63","author":"Alami NN","year":"2014","unstructured":"Alami NN, Yuen CM, Miramontes R, Pratt R, Price SF, Navin TR. 2014. Trends in tuberculosis\u2013United States, 2013. MMWR Morb Mortal Wkly Rep 63:229\u2013233.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_4_2","first-page":"265","article-title":"Tuberculosis trends\u2013United States, 2014","volume":"64","author":"Scott C","year":"2015","unstructured":"Scott C, Kirking HL, Jeffries C, Price SF, Pratt R. 2015. Tuberculosis trends\u2013United States, 2014. MMWR Morb Mortal Wkly Rep 64:265\u2013269.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0503OC"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/320512"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200509-1531OC"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-09"},{"key":"e_1_3_2_9_2","first-page":"905","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS","volume":"121","author":"Chaisson RE","year":"1994","unstructured":"Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 121:905\u2013911.","journal-title":"AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.3.9811086"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu610"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ427"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00749-10"},{"key":"e_1_3_2_14_2","first-page":"S38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","author":"Drusano GL","year":"1997","unstructured":"Drusano GL, Craig WA. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 9(Suppl 3):S38\u2013S44.","journal-title":"J Chemother"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.12part2.150S"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05546-11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2450-2457.2003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn032"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq398"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.12.005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03549-14"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku136"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1614"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.3.539"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1949.10483310"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01761-09"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0682OC"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01520-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh519"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.08.001"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2577"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.147"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/317441"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku207"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.113"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80046-1"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis353"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000436"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir658"},{"key":"e_1_3_2_46_2","article-title":"Cuddling nightmare bacteria: amikacin pharmacokinetics\/pharmacodynamics in a novel hollow fiber Mycobacterium abscessus disease model","author":"Ferro BE","year":"2015","unstructured":"Ferro BE, Srivastava S, Deshpande D, Sherman CM, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T. 2015. Cuddling nightmare bacteria: amikacin pharmacokinetics\/pharmacodynamics in a novel hollow fiber Mycobacterium abscessus disease model. Antimicrob Agents Chemother [Epub ahead of print].","journal-title":"Antimicrob Agents Chemother [Epub ahead of print]"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02854-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02854-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:33:44Z","timestamp":1645457624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02854-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1128\/AAC.02854-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02854-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"2015-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}